FDA Announces Determination of Regulatory Review Period for OMVOH Patent Extension
May 14, 2025
May 14, 2025
WASHINGTON, May 14 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) has published a notice regarding the determination of the regulatory review period for OMVOH (mirikizumab), a human biological product developed by Eli Lilly and Co.
This product is approved for the treatment of moderately to severely active ulcerative colitis in adults. The determination, made in collaboration with the U.S. Patent and Trademark Office (USPTO), establish . . .
This product is approved for the treatment of moderately to severely active ulcerative colitis in adults. The determination, made in collaboration with the U.S. Patent and Trademark Office (USPTO), establish . . .